Czamara, Darina http://orcid.org/0000-0001-7381-904X
Neufang, Alexa
Dieterle, Roman
Iurato, Stella
Arloth, Janine
Martins, Jade
Ising, Marcus
Binder, Elisabeth E.
Erhardt, Angelika
Funding for this research was provided by:
Eranet Neuron AnxBio (01EW1401A)
Max Planck Institute of Psychiatry
Article History
Received: 21 January 2022
Accepted: 7 April 2022
First Online: 27 April 2022
Declarations
:
: The Ethics Committee of the Ludwig Maximilians University, Munich, Germany, in accordance with the Declaration of Helsinki approved all procedures.
: Not applicable.
: EB is the coinventor of FKBP5: a novel target for antidepressant therapy, European Patent no. EP 1687443 B1, and receives a research grant from Böhringer Ingelheim for a collaboration on functional investigations of FKBP5. It has to be noted that SI is now a full-time employee at Roche Diagnostics GmbH and JM is a full-time employee at Capgemini Deutschland GmbH. Otherwise, the authors declare that they have no competing interests.